Expectations are ultra low. With a market cap of $200 million the stock is priced for NeuVax's failure. Yet, with a 78% reduction in recurrence and no approved drugs to prevent recurrence in low-intermediate levels of HER2, Galena has a great shot.
Abstral is flying under-the-radar, has now launched and has zero expectations. If sales are even remotely decent, GALE will fly.
Worst case scenario, Abstral flops and NeuVax fails, GALE is a $0.50 stock.
Best Case = Abstral $100m and NeuVax has great preliminary data = GALE a $15 stock.